Email this article Influence of gender and age of patients with oral mucosa cancer on the phenotype of systemic and local immunity
- Authors: Zabotina T.N.1, Chertkova A.I.1, Borunova A.A.1, Zakharova E.N.1, Shoua E.K.1, Shoua I.B.1, Tsiklauri V.T.1, Zaderenko I.A.1, Kadagidze Z.G.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 21, No 2 (2022)
- Pages: 47-55
- Section: ORIGINAL REPORTS
- Published: 26.07.2022
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1327
- DOI: https://doi.org/10.17650/1726-9784-2022-21-2-47-55
- ID: 1327
Cite item
Full Text
Abstract
Background. The incidence of oral mucosa cancer (OMC) is higher in people over 50 years of age, and the aggressiveness of the course of the disease is higher in people under 50 years of age. In this context, it is of interest to clarify the mechanisms of immune disorders characteristic of patients of different age groups.
Aim. To research systemic and local immunity in OMC patients and the relationship of peripheral blood lymphocyte population (PBLs) and tumor infiltrating lymphocytes (TILs) with the patient’s sex and age.
Materials and methods. PBLs and TILs effector and suppressor populations were studied by flow cytometry in OMC patients aged 29 to 84 years.
Results. The percentage of CD3-, CD3+CD4+ and CD3+CD8+T cells, regulatory CD4+CD25+CD127low/ –(CD4Treg) and CD8+CD11b–CD28–(CD8Тreg) T lymphocytes, CD4+PD-1+ and CD8+PD-1+ T cells was increased in TILs compared to PBLs. The levels of cytotoxic CD8+CD11b+CD28– T lymphocytes, NK, CD8+Perforin+ and CD16+Perforin+ cells in TILs were lower than in PBLs. The relationship between the level of CD4Treg and other TILs and PBLs depended on the patient’s sex. Age-related changes in the levels of NK and CD8 T-cells were observed in men, and CD4Treg – in women.
Conclusion. Local immunity in OMC patients is highly immunosuppressive. The sex of patients influences the relationship between CD4Treg and other populations of PBLs and TILs, as well as age-related changes in the OMC patients’ immune system. This investigation results can make a certain contribution to personalized treatment of patients with OMC, taking into account differences in systemic and local immunity and in the immune response to the tumor in patients of different sex and age.
About the authors
T. N. Zabotina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: tatzabotina@yandex.ru
ORCID iD: 0000-0001-7631-5699
Tatiana Nicolaevna Zabotina
24 Kashirskoe Shosse, Moscow 115478
Russian FederationA. I. Chertkova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0001-9146-5986
Antonina I. Chertkova
24 Kashirskoe Shosse, Moscow 115478
Russian FederationA. A. Borunova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-1854-3455
Anna A. Borunova
24 Kashirskoe Shosse, Moscow 115478
Russian FederationE. N. Zakharova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0003-2790-6673
Elena N. Zakharova
24 Kashirskoe Shosse, Moscow 115478
Russian FederationE. K. Shoua
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0003-3937-474X
Esma K. Shoua
24 Kashirskoe Shosse, Moscow 115478
Russian FederationI. B. Shoua
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-9488-4710
Ilona B. Shoua
24 Kashirskoe Shosse, Moscow 115478
Russian FederationV. T. Tsiklauri
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-3090-695X
Vasily T. Tsiklauri
24 Kashirskoe Shosse, Moscow 115478
Russian FederationI. A. Zaderenko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0003-0183-4827
Igor A. Zaderenko
24 Kashirskoe Shosse, Moscow 115478
Russian FederationZ. G. Kadagidze
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-0058-0987
Zaira G. Kadagidze
24 Kashirskoe Shosse, Moscow 115478
Russian FederationReferences
- Dhanuthai K., Rojanawatsirivej S., Thosaporn W. et al. Oral cancer: a multicenter study. Med Oral Patol Oral Cir Bucal 2018;23(1):e23–e9. doi: 10.4317/medoral.21999
- Yokota T., Homma A., Kiyota N. et al. Head and neck cancer study group. Immunotherapy for squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2020;50(10):1089–96. doi: 10.1093/jjco/hyaa139
- Deng W.W., Li Y.C., Ma S.R. et al. Specific blockade CD73 alters the “exhausted” phenotype of T cells in head and neck squamous cell carcinoma. Int J Cancer 2018;143(6):1494–504. doi: 10.1002/ijc.31534
- Fenoglio D., Belgioia L., Parodi A. et al. Development of exhaustion and acquisition of regulatory function by infiltrating CD8+ CD28 – T Lymphocytes dictate clinical outcome in head and neck cancer. Cancers (Basel) 2021;13(9):2234. doi: 10.3390/cancers13092234
- Chen J., Yang J., Li H. Single-cell transcriptomics reveal the intratumoral landscape of infiltrated T-cell subpopulations in oral squamous cell carcinoma. Mol Oncol 2021;5(4):866–86. doi: 10.1002/1878-0261.12910
- Cohen E.E.W., Soulières D., Le Tourneau C. et al. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. doi: 10.1016/S0140-6736(18)31999-8
- Johnson D.E., Burtness B., Leemans C.R. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6(1):92. doi: 10.1038/s41572-020-00224-3
- Raskov H., Orhan A., Christensen J.P., Gögenur I. Cytotoxic CD8 + T cells in cancer and cancer immunotherapy. Br J Cancer 2021;124(2):359–67. doi: 10.1038/s41416-020-01048-4
- Zabotina T.N., Korotkova O.V., Borunova A.A. et al. Multiparameter study of the immunophenotype of lymphocytes infiltrating the tumor in cancer patients. Rossiiskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2016;21(1–2):51–4. (In Russ.). doi: 10.18821/1028-9984-2015-21-1-51-54
- Zabotina T.N., Chertkova A.I., Tsiklauri V.T. et al. Features of peripheral blood lymphocytes and tumor infiltrating lymphocytes subpopulations in patients with squamous cell head and neck cancer. Immunologiya = Immunology 2019;40(3):10–9. (In Russ.). doi: 10.24411/0206-4952-2019-13002
- Zabotina T.N., Chertkova A.I., Borunova A.A. et al. Relationship of lymphocyte subpopulations in breast cancer patients with treatment results. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2021;20(3):25–33. (In Russ.). doi: 10.17650/1726-9784-2021-20-3-25
- Zhao Y., Shao Q., Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol Immunol 2020;17(1):27–35. doi: 10.1038/s41423-019-0344-8
- Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015;15(8):486–99. doi: 10.1038/nri3862
- Davoodzadeh Gholami M., Kardar G.A., Saeedi Y. et al. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 2017;322:1–14. doi: 10.1016/j.cellimm.2017.10.002
- Yang F., Zeng Z., Li J., Ren X., Wei F. IM-3 and CEACAM1 are prognostic factors in head and neck squamous cell carcinoma. Front Mol Biosci 2021;8:619765. doi: 10.3389/fmolb.2021.619765
- Kurachi M. CD8(+) T cell exhaustion. Semin Immunopathol 2019;41(3):327–37. doi: 10.1007/s00281-019-00744-5
- Jiang W., He Y., He W. et al. Exhausted CD8 + T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol 2021;11:622509. doi: 10.3389/fimmu.2020.622509
- Zhang C., Liu Y. Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy. Front Immunol 2020;11:1295. doi: 10.3389/fimmu.2020.01295
- Penaloza-MacMaster P., Kamphorst A.O., Wieland A. et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 2014;211(9):1905–18. doi: 10.1084/jem.20132577
- Pawelec G. Does patient age influence anti-cancer immunity? Semin Immunopathol 2019;41(1):125–31. doi: 10.1007/s00281-018-0697-6
- Irelli A., Sirufo M.M., D’Ugo C. et al. Sex and gender influences on cancer immunotherapy response. Biomedicines 2020;8(7):232. doi: 10.3390/biomedicines8070232
- Henson S.M., Riddell N.E., Akbar A.N. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol 2012;24(4):476–81. doi: 10.1016/j.coi.2012.04.001
- Mirandola L., Wade R., Verma R. et al. Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol 2015;34(2):134–42. doi: 10.3109/08830185.2015.1018417
- Gubbels Bupp M.R., Potluri T., Fink A.L., Klein S.L. The confluence of sex hormones and aging on immunity. Front Immunol 2018;9:1269. doi: 10.3389/fimmu.2018.01269
- Capone I., Marchetti P., Ascierto P.A. et al. Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy. Front Immunol 2018;9:552. doi: 10.3389/fimmu.2018.00552
Supplementary files
